La Jolla, CA — Sun Microsystems, Inc. and Molecular Simulations, Inc. (MSI), a wholly owned subsidiary of Pharmacopeia, Inc., announced their collaboration to deliver advanced dot-com grade solutions spanning the drug discovery pipeline. Leveraging the robust, scalable and highly-reliable Solaris Operating Environment, Sun and MSI will enable cheminformatics and bioinformatics researchers to deploy MSI’s solutions across networked environments and through application service providers (ASPs). The collaboration aims to open new markets for MSI’s bioinformatics and structural biology products, and demonstrates Sun’s strengthened commitment to dot-com the discovery process.
MSI, a leading cheminformatics software provider with licenses in most major pharmaceutical companies worldwide, has named Solaris as a premier platform for product development and deployment. To support the extension of MSI’s technologies, Sun is working closely with MSI to port MSI’s MODELER, SeqFold, CHARMm, DelPhi, and CNX products onto the Solaris platform. MSI expects to continue broadening its potential user base by porting more products to Solaris.
By porting to Solaris and using the Sun platform for development, MSI will be able to offer its customers enterprise-wide deployment of its solutions through a client-server model. In addition, MSI’s adoption of the Sun platform will enable the company to provide thousands of informatics professionals worldwide access to its solutions through Sun-powered ASPs.
“Sun is excited to be working with MSI in our continuing effort to deliver powerful solutions to dot-com the discovery pipeline,” said Doug Kaewert, vice president, Market Development, Sun Microsystems. “By aligning our companies’ best-of-breed solutions, Sun and MSI are offering cheminformatics and bioinformatics professionals unprecedented access to the tools they need to take ideas from the laboratory and into the world beyond.”
“This agreement will increase the impact of both MSI and Sun’s solutions in pharmaceutical discovery and especially in the field of functional genomics,” said Dr. Scott Kahn, senior vice president, Life Science Research and Development, MSI. “Sun has a strong track record of helping to drive the bioinformatics industry, and I am delighted that we are joining forces to provide the structural prediction tools that will address the needs of the post-genomic era.”
Since its inception in 1982, a singular vision The Network Is The Computer‰ – has propelled Sun Microsystems, Inc., to its position as a leading provider of industrial-strength hardware, software and services that power the Internet and allow companies worldwide to dot-com their businesses. With $15.7 billion in annual revenues, Sun can be found in more than 170 countries and on the World Wide Web at http://www.sun.com .
Molecular Simulations Inc. (MSI) is a leading provider of simulation software for predicting the structure and properties of biological and chemical systems. Its software helps the world’s foremost industrial research teams to solve commercially significant problems and accelerate product discovery and development. MSI is a subsidiary of Pharmacopeia, Inc. For more information visit http://www.msi.com .